INTRODUCTION
The availability of antiretroviral therapy (ART) has dramatically changed the face of the HIV pandemic with a major improvement of life expectancy. However, at the same time, it was realized that some patients with HIV infection develop a paradoxical worsening of clinical status after the initiation of ART. This has been termed immune reconstitution inflammatory syndrome (IRIS) [1] [2] [3] . As the viral load diminishes and the immune system recovers, patients may develop immune disease either in the periphery or in the central nervous system (CNS). Although the term IRIS has been used to describe the more severe form of inflammation and is thereby recognizable from clinical signs, it is becoming increasingly apparent that IRIS is a spectrum disorder and may range in severity and chronicity. All patients with HIV infection managed with ART undergo acute immune dysregulation and chronic inflammation and immune dysfunction [4, 5] that may contribute to HIV-associated diseases, such as stroke [6] , autoimmunity [7, 8] , HIV-associated neurological disorders (HANDs) [9, 10] , cancer [11, 12] and premature aging [13] [14] [15] .
Understanding the consequences of immune reactivation in the context of HIV infection has taken up new importance as current strategies for
INCIDENCE OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AND CENTRAL NERVOUS SYSTEM-IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME
A meta-analysis of 17 cohorts, not restricted in the type of IRIS, estimated an IRIS incidence ranging from 3 to 39% [21] . Retrospective studies from Mexico [22] and Mozambique [23] of 390 and 136 patients, respectively, initiating ART indicate that the incidence of IRIS is approximately 27%. The vast majority of IRIS cases are associated with opportunistic infections either recognized prior to initiation of ART but worsening after therapy (paradoxical IRIS) or recognized after therapy initiation due to the restoration of the immune system (unmasking IRIS) (Fig. 1) . The overall incidence of CNS-IRIS inclusive of all patients initiating ART is estimated to be approximately 1% [24] . However, similar to IRIS, CNS-IRIS often occurs within the context of an opportunistic infection and therefore, the incidence of CNS-IRIS is frequently assessed in populations with a particular opportunistic infection. Thus, the incidence of CNS-IRIS is highly variable, averaging 15-25% and ranging upwards of 40% in highrisk individuals [25] [26] [27] [28] 29 && ]. A study of 110 consecutive patients with HIV and a diagnosed CNS opportunistic infection demonstrated the occurrence of CNS-IRIS to be 16.4% [29 && ]. Similarly, a study of 620 patients admitted to hospital with new or worsening neurological disease and HIV demonstrated an overall CNS-IRIS incidence of 11.8% [26] ; however, 40% of patients with CNS tuberculosis (TB) in this cohort developed CNS-IRIS. The wide range in incidence of CNS-IRIS reflects diagnostic challenges and regional resource availability, but also may represent biological consequences related to specific pathogen associations and disease mechanisms.
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME: MORTALITY AND RISK FACTORS
IRIS is now recognized as a significant cause of morbidity and mortality in the HIV-managed population. IRIS is associated with an increased risk of mortality (mortality ratio of 2.3) and hospitalization (three-fold risk) after adjusting for confounding factors (22) . Similar trends in mortality were found in another adult [23] and a pediatric cohort [30 & ]. Although CNS-IRIS is a smaller proportion of all IRIS cases, it represents the most debilitating form of IRIS and is associated with death or permanent neurological deficit in an estimated 16-50% of cases [27,29 && ,31,32] . The CD4 nadir, an indicator of the degree of immune suppression, and the presence of an opportunistic infection at the time of initiation of ART are the greatest risk factors for the development of IRIS [3, 22, 33] . A reduced BMI was also independently associated with the development of IRIS in two separate cohorts; however, occurrence of CNS-IRIS was not included in the analysis [22, 23] .
KEY POINTS
CNS-IRIS in the absence of opportunistic infections may be much more common than originally found and may range from acute fulminant forms to chronic forms that lead to progressive T cell-mediated neurodegeneration.
In the subacute or chronic forms of CNS-IRIS despite adequate control of HIV replication, there is continued release of HIV-Tat protein which is a potent activator of T cells and results in a T cell-mediated encephalitis.
In patients with opportunistic infections and CNS-IRIS, antiretrovirals should be delayed by a few weeks if antimicrobials are available to treat the opportunistic infection. However, in patients with progressive multifocal leukoencephalopathy (PML), antiretrovirals should not be delayed even at the risk of developing IRIS.
Extreme caution is necessary in the use of therapeutic strategies that are on the basis of reactivation of viral reservoirs, as they may result in IRIS within the brain. ]. Other opportunistic infections, such as varicella zoster virus [41] [42] [43] , Cytomegalovirus [44, 45] , Candida species [46] and Toxoplasma gondii [47] [48] [49] , are associated with CNS-IRIS but contribute to the frequency of disease at much reduced rates as compared with cryptococcal meningitis and TB infections. Studies on the prevention of CNS-IRIS suggest that a one-size-fits-all approach is not appropriate once a patient is immune compromised. Ideally, early detection of HIV infection through routine screening would enable initiation of therapy before CD4 þ T cell counts are below 500 [50] , or if resources are available, immediately after diagnosis of HIV infection. By preventing the immune system from becoming compromised, some of the risk of immune dysregulation and IRIS are avoided. If HIV infection is diagnosed in patients who are already immune compromised, careful screenings for CNSopportunistic infections prior to ART initiation should be completed. Reducing the antigenic burden within the CNS may help prevent adverse neurologic inflammation. Delaying ART for 5 weeks to first treat cryptococcal meningitis has been shown to improve survival, although there was no statistically significant difference in occurrence of CNS-IRIS (early ART ¼ 20% IRIS, delayed ART ¼ 13% IRIS) [51 && ]. In contrast, it is essential to begin ART immediately if JCV infection is detected within the CNS regardless of the risk of IRIS as the immune system is the only current defense against this pathogen and corticosteroids have shown some benefit if CNS-IRIS does occur [39, 40] . In a study of immediate versus delayed ART in 806 patients with TB, 61 patients developed IRIS of which four developed CNS-IRIS. Of these four patients, 75% received early ART and 25% received delayed ART [52 & ]. In the case of tuberculosis meningitis delaying ART reduced the most severe adverse clinical events but did not impact mortality [53] . Therefore, it is currently recommended that in the case of tuberculosis meningitis ART be delayed 4 weeks [34 && ].
CENTRAL NERVOUS SYSTEM-IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AND HIV ENCEPHALITIS
Although not considered an opportunistic infection, residual or untreated HIV replication within the CNS may lead to HIV encephalitis and may also contribute to the development of CNS-IRIS and chronic inflammation. IRIS is distinct from neurological complications associated with viral replication in the CNS and therapy failure, although clinically the presentation may mimic IRIS and may involve inflammation [54, 55] . Elevated CNS viral loads, even in the presence of reduced viral loads in the periphery, may result not only in CNS inflammation but also in neurotoxicity and neurodegeneration from viral products [56] [57] [58] [59] [69, 70] , nausea [69] , hearing impairment [69] , weakness [70, 71] , impaired speech [71] , disorientation and ataxia [72 && ] or ischemic events [6] . Although the exact forces driving the immune system are not well defined, the immune response may be directed at residual virus in the CNS, persistent release of HIV-Tat protein from HIV-infected cells despite control of viral replication or to self-antigens (Fig. 2) . In one well studied cohort of 10 patients treated with ART who developed subacute encephalopathy, biopsy pathology demonstrated robust CD8 þ lymphocyte infiltration both in the parenchyma and perivascular regions [65
&&
]. Furthermore, reactive astrocytosis and microglial activation were ubiquitous. Axonal damage and loss of myelin were observed in a subset of patients. When corticosteroids were initiated in these patients, 60% showed improvement neurologically and had decreased presence of CNS lymphocytes. The other patients continued to deteriorate with 40% fatality in this cohort [65 && ]. Within this cohort, six patients had increasing viral loads that may indicate that the immune response was targeted at HIV. However, three of the patients developed neurological symptoms after the initiation of ART without an increase in viral load: one at 3 months, one at 9 months and one at 2 years post-ART-initiation, all coinciding with increasing CD4 þ cell counts [65
]. All of these findings are highly suggestive of IRIS. Importantly, of these patients, 66% (two out of three) improved with corticosteroids and 33% (one out of three) died.
ACUTE VERSUS CHRONIC IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME
In addition to suggesting that IRIS may mimic HIVmediated encephalitis, this cohort also supports the concept of acute and chronic IRIS (Fig. 3) . Two of the three patients developed immune disease within a year of initiating ART, whereas one patient developed immune disease 2 years after initiation of ART [65 && ,66 && ]. Case reports of CNS-IRIS in the absence of opportunistic infections suggest that there can be varying degrees of onset and severity. A case report describes a patient with rapid immune recovery (CD4 þ count 133-1251 cells/ml in 3 months) and severe neurological impairment including deafness that improved with corticosteroid treatment [69] . Biopsy showed infiltrating lymphocytes, primarily CD8 þ cells, neuronal loss and fibrous astrocytosis. This patient showed substantial neurological improvement and returned to work. In this case, the presence of HIV in the CNS was not examined. In a separate report, a patient developed neurological complications 10 years after initiation of ART. Initially treated with corticosteroids, the patient improved and 2 years later relapsed with ongoing neurological complications. Corticosteroids were again employed with slight improvement. After an additional 2-year interval modification to ART regime to improving CNS penetration was included as well as an additional corticosteroid intervention. Brain biopsy showed robust CD8 þ lymphocytic infiltrates, some CD4 þ cells and occasional interleukin -17 þ cells. There were no HIV p24 in the CNS but robust levels of HIV Tat [72 && ]. This patient has a permanent cognitive impairment. Similar cases have been reported. In a cohort of six patients examined for suspected IRIS, one developed neurological complications 10 years after ART initiation with CD8 þ parenchymal and perivascular infiltrates and lasting sequelae, whereas one patient developed neurological signs 5 months after ART initiation. Immune restoration was rapid and dramatic and biopsy showed CD8 þ infiltrates. The patient improved with CNS penetrating ART [70] . Other reports indicate IRIS may occur 2 years after initiation of ART, with recurrent bouts of resolving neurological complications [68] or as severe neurological manifestations 3 weeks after ART initiation that improved with corticosteroid use but worsened and caused fatality during corticosteroid taper [71] . Together, these cases, in conjunction with the previously described cohort, suggest that IRIS may develop in an acute or chronic form (summarized in Table 1 ). Both forms of IRIS are associated with increasing CD4 þ cell counts, and therefore, are a reflection of ongoing immune restoration. Immune response in these patients may be targeted against replicating virus in the brain or HIV-Tat protein if viral replication is controlled by ART.
CHRONIC IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AND NEUROCOGNITIVE IMPAIRMENT
Although ART has reduced the occurrence of HIVassociated dementia dramatically [73] , HAND persists and even asymptomatic cognitive impairment heralds the risk of further cognitive decline [74 & ]. Interestingly, similar to IRIS, the risk of neurocognitive impairment is also tightly correlated with a lower CD4 nadir [75] suggesting that immune depletion then restoration plays an important role in the development of HAND. It is likely that viral entry into the brain occurs during the time of immune depletion and immune restoration targets the virus or viral products in the brain. Preliminary data from our laboratory suggest that nearly 30-40% of patients with undetectable HIV in the cerebrospinal fluid (CSF) still have detectable HIVTat protein, suggesting that it may drive the chronic IRIS and associated neurocognitive impairment. Furthermore, the chronic IRIS form is often associated with recurrent bouts of neurological manifestations that can improve under corticosteroid therapy [68,72 && ]. This is similar to some autoimmune disorders, such as multiple sclerosis in its relapsing-remitting form [76] . The pathobiological mechanisms driving chronic IRIS may be informative for autoimmune diseases in which an underlying pathogen is suspected but not detected.
Approaches to treatment
As discussed above, corticosteroids have been often used to treat CNS-IRIS. Although short-term use of corticosteroids seems safe, long-term use has the potential for development to opportunistic infections and other know sequelae such as bone mineral loss and adrenal suppression. Hence, other approaches need to be considered. In patients with viral escape, that is, who have higher viral loads in the CSF compared with the blood, antiretroviral regimen should be altered to include those who have a higher CNS penetration. In patients who develop autoimmune responses to CNS antigens, therapies that block lymphocyte trafficking into the CNS such as natalizumab may be considered. This is preferable to other drugs that target activated lymphocytes, as natalizumab leaves the peripheral immune system intact. However, due to the risk of PML associated with this drug only patients known to be negative for antibodies to JC virus should be treated. Patients with detectable Tat protein in CSF in the absence of detectable HIV should ideally be treated with a Tat antagonist. However, in the absence of such a compound, T cell trafficking to the brain should be controlled as mentioned above.
CONCLUSION
CNS-IRIS and chronic CNS inflammation in HIVinfected populations is a serious complication associated with ART. The syndrome has a varied clinical presentation with acute to chronic forms and thus remains under recognized. Treatment strategies may vary depending on the underlying pathophysiological mechanism but patients should be continued on a CNS penetrating ART regimen with aggressive treatment of an underlying opportunistic infection and liberal use of corticosteroids as necessary. Acute forms of CNS-IRIS may be prevented by starting ART early in the course of infection, delaying ART in patients with opportunistic infections being treated with antimicrobials and avoiding strategies that lead to activation of viral reservoirs. 
